How Much Does It Cost to Provide Antiretroviral Therapy  for HIV/AIDS in Africa? by Rosen, Sydney & Long, Lawrence
Boston University
OpenBU http://open.bu.edu
Department of Global Health SPH Health & Development Paper Series
2010-01-28T20:02:08Z
How Much Does It Cost to Provide
Antiretroviral Therapy for HIV/AIDS
in Africa?
http://sph.bu.edu/cihd/index.php?option=com_content&task=view&id=381&Itemid=617095
Boston University
 
  
 
 
 
Center for International Health and Development 
Boston University 
 
 
How Much Does It Cost to Provide 
Antiretroviral Therapy  
for HIV/AIDS in Africa? 
 
 
 
Sydney Rosen and Lawrence Long 
 
 
 
 
Health and Development  
Discussion Paper No. 9 
October 2006 
 
 
 
 
 
Center for International Health and Development 
Boston University School of Public Health 
85 East Concord St., 5th fl. 
Boston, MA  02118  USA 
Cost of antiretroviral therapy in Africa  HDDP9 
 2
 Abstract 
 
Background:  Many African countries are rapidly expanding HIV/AIDS treatment programs.  
Empirical information on the cost of delivering antiretroviral therapy (ART) for HIV/AIDS is 
needed for program planning and budgeting.   
 
Methods:  We searched published and gray sources for estimates of the cost of providing 
ART in service delivery (non-research) settings in sub-Saharan Africa.  Estimates were 
included if they were based on primary local data for input prices.   
 
Results:  17 eligible cost estimates were found.  Of these, 10 were from South Africa.  The 
cost per patient per year ranged from $396 to $2,761.  It averaged approximately 
$850/patient/year in countries outside South Africa and $1,700/patient/year in South Africa.  
The most recent estimates for South Africa averaged $1,200/patient/year.  Specific cost items 
included in the average cost per patient per year varied, making comparison across studies 
problematic.  All estimates included the cost of antiretroviral drugs and laboratory tests, but 
many excluded the cost of inpatient care, treatment of opportunistic infections, and/or clinic 
infrastructure.  Antiretroviral drugs comprised an average of one third of the cost of treatment 
in South Africa and one half to three quarters of the cost in other countries. 
 
Conclusions:  There is very little empirical information available about the cost of providing 
antiretroviral therapy in non-research settings in Africa.  Methods for estimating costs are 
inconsistent, and many estimates combine data drawn from disparate sources.  Cost analysis 
should become a routine part of operational research on the treatment rollout in Africa. 
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Introduction 
 
As of June 2006, an estimated 1.04 million people in sub-Saharan Africa were receiving 
antiretroviral therapy (ART) for HIV/AIDS.  This number, while still accounting for fewer 
than a quarter of those deemed to be in need, represents a ten-fold expansion of treatment 
services since late 2003.  During the first half of 2006, new patients were added at a rate of 
some 38,000 per month, according to World Health Organization estimates.[1] 
 
Treatment is being paid for by a combination of domestic government budget allocations, 
patients’ own resources, and international donor grants.  Since both the maintenance of 
current service delivery and expansion of access to the remaining three quarters in need will 
require substantial new investments in the years to come, it is important to know how much 
the provision of antiretroviral therapy costs.  In the absence of prior experience in delivering 
ART in the public sector, original estimates of the resources needed for treatment were based 
on models that generally pieced together costs from disparate local sources and/or adjusted 
cost data collected from other parts of the world.[2,3] 
 
Many countries now have more than two years of experience in providing ART on a large 
scale in public sector facilities, and longer experience in nongovernmental and private sector 
facilities.  Several reports of clinical outcomes for large patient cohorts at these sites have 
already been published.[4–9]  It is thus reasonable to expect that cost estimates based on 
actual experience are now available to policy makers and planners and can be used to 
improve future resource planning.  We conducted a review of the published literature, gray 
literature, and conference abstracts to locate empirical estimates of the costs of providing 
ART in service delivery (non-research) settings in sub-Saharan Africa.   
 
Methods 
 
Studies were included in the review if they contained estimates of the provider costs of 
treating adult patients with antiretroviral therapy in a service delivery setting, which we 
defined as any setting other than that of a clinical trial.  Eligible settings thus included public, 
private, nongovernmental, and workplace facilities.  We originally intended to restrict the 
review to estimates based on primary, retrospective data on resources actually expended for a 
treated population.  Because we found so few of these, we expanded the search to include 
estimates that used primary local data for input prices but modeled resource use either from 
expected treatment regimens and schedules of services or from local clinical trial populations, 
with research-specific costs excluded.  We excluded studies that did not indicate the sources 
of unit cost estimates or used non-local input prices.  
 
Using the terms “antiretroviral,” “cost,” and “Africa,” eligible studies were sought on 
Medline, the Social Science Citation Index, and Google.  Abstracts of the last six 
international conferences of the International AIDS Society and other relevant national and 
international conferences and publications archives were also searched, as were the websites 
of research organizations and international agencies.  We also reviewed bibliographies of 
relevant papers and asked health economists and other researchers working in sub-Saharan 
Africa for relevant sources.  Where possible, authors of conference abstracts were contacted 
to ask if a full paper, poster, or slide presentation was available; results from the abstract were 
included if more detailed information was not provided.  No effort was made to verify or 
refine the cost estimates beyond what was included in the source documents. 
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Results 
 
We located 15 studies that met the criteria for the review.  One of these estimated treatment 
costs at three types of sites, giving us a total of 17 cost estimates.  The studies are listed in 
Table 1.  Study reference numbers in Table 1 will be used to refer to individual studies in the 
remainder of the paper. 
 
Table 1.  Studies Included in the Review 
 
Study 
reference 
number 
Source Country and 
location 
Setting Type of facility No. 
facilities 
included in 
costing 
Population 
treated 
No. study 
subjects 
included 
in costing 
Year of cost 
data 
B1 [10] Benin, 
Cotonou 
Urban Nongovernmental 
clinic 
1 Assumed 
general 
adults 
237 2005 
C1 [11-13] Cote d'Ivoire, 
Abidjan 
Urban Community clinics 5 Clinical trial 
participants 
(adults) 
270  Unclear, 
probably 2000 
E1 [14] Ethiopia, 
various 
locations 
Unspec. Public hospitals 6 Assumed 
general 
adults 
n.a. Unclear, 
probably 2003 
N1 [15] Nigeria, 
various 
locations 
Unspec. Various 5 Assumed 
general 
adults 
n.a. 2001-2004 
R1 [16] Rwanda, 
various 
locations 
Unspec. Reference 
hospitals, district 
hospitals, and 
health centers 
9 Assumed 
general 
adults 
109 2005 
SA1 [17] South Africa, 
Cape Town 
Urban Teaching hospital 1 Clinical trial 
participants 
(adults) 
27 2004 
SA2 [18] South Africa, 
various 
locations 
Various 
settings 
(mining 
areas) 
Hospitals Many  Mine 
employees 
and 
dependents 
Unspec. Unclear, 
probably 
2002-2005 
SA3 [18] South Africa, 
various 
locations 
Various 
settings 
(mining 
areas) 
Occupational 
clinics 
Many  Mine 
employees 
and 
dependents 
Unspec. Unclear, 
probably 
2002-2005 
SA4 [18] South Africa, 
various 
locations 
Various 
settings 
(mining 
areas) 
General 
practitioners' 
offices 
Many  Mine 
employees 
and 
dependents 
Unspec. Unclear, 
probably 
2002-2005 
SA5 [19] South Africa 
Cape Town 
Urban Nongovernmental 
clinics 
3 Assumed 
general 
adults 
1729 2000-2005 
SA6 [20] South Africa, 
various 
locations 
Various 
settings 
(workfor
ces) 
Managed care 
scheme 
Many Employed 
persons 
and 
dependents 
Unspec. 2002 
SA7 [21] South Africa, 
Durban 
Urban Hospitals 2 Healthcare 
workers 
41 2004 
SA8 [22] South Africa, 
Cape Town 
Urban Public dedicated 
HIV clinic 
1 Assumed 
general 
adults 
212 Unspec., 
probably 2005 
SA9 [23,24] South Africa, 
Soweto 
Urban Nongovernmental 
clinic 
1 General 
adults 
980 2004-2005 
SA10 [25] South Africa, 
Johannesburg 
Urban Public hospital 1 General 
adults 
100 2005 
U1 [26] Uganda, 
Unspec. 
Unspec. Various Unspec. Assumed 
general 
adults 
Unspec. 2004 
ZI [27] Zambia, 
Unspec. 
Unspec. No individual 
facilities 
n.a. Assumed 
general 
adults 
n.a. 2002-2003 
Unspec:  Unspecified. 
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Cost estimates from the studies are shown in Table 2 and Figure 1.  From each study, we 
extracted or calculated an average annual cost per patient for the first year of treatment.  
Whenever possible, this covered a full twelve months on antiretroviral therapy for all patients 
included in the cost estimate.  A few studies, however, included some patients not yet on 
ART in the average cost estimate, and others were ambiguous on this point.  Almost all of the 
studies looked only at patients still on ART at the end of the costing period, thereby 
excluding the costs of mortality and loss to follow up of patients who initiated therapy.  
Finally, some studies considered only patients on first-line ARVs, while others included 
actual or estimated costs for patients who switched to second-line drugs during the year.  
Table 2 notes these issues for each study.   
 
Table 2.  Cost Estimates  
 
Study 
reference 
number 
Average 
cost/ 
patient/ 
year (USD) 
USD 
year 
Costing methods Costs included Major costs 
excluded 
Inclusion of 
2nd-line ARV 
regimen 
B1 $2,000 N.A. Average cost per ART 
patient based on patient 
and site records. 
ARVs, lab, OI 
treatment, inpatient 
care, personnel. 
Infrastructure 
unclear. 
Unspecified 
C1 $1,180 2002 Disease progression data 
from local clinical trial 
combined with local 
regimen and input prices.a 
ARVs, lab, OI 
treatment , inpatient 
care, personnel, 
infrastructure. 
 1st line only. 
E1 $705 2003 Local regimen and input 
prices, modeled with 
AIDSTreatCost 
ARVs, lab, 
personnel. 
OI treatment, 
inpatient care, 
infrastructure. 
1st line only. 
N1 $742 2004 Local regimen and input 
prices, modeled with 
AIDSTreatCost. 
ARVs, lab, 
personnel.  ARV and 
lab costs increased 
by 15% to account 
for wastage. 
OI treatment, 
inpatient care, 
infrastructure. 
1st line only. 
R1 $396 2005 Average cost per ART 
patient based on patient 
and site records.  
ARVs, lab, OI 
treatment, inpatient 
care, personnel. 
Infrastructure 
unclear. 
Unspecified 
SA1 $1,513 2004 Resource use data from 
local clinical trial combined 
with current input prices.  
ARVs, lab, OI 
treatment, inpatient 
care, personnel.  
Includes TB 
treatment. 
Infrastructure. Unspecified 
SA2 $2,287 2005 Average cost per ART 
patient based on patient 
and site records. 
ARVs, lab, 
personnel, 
infrastructure, 
management 
OI treatment  and 
inpatient care 
unclear. 
2% of 
subjects 
switched to 
2nd line 
ARVs over 
costing 
period. 
SA3 $2,514 2005 Average cost per ART 
patient based on patient 
and site records. 
ARVs, lab, 
personnel, 
infrastructure, 
management 
OI treatment  and 
inpatient care 
unclear. 
2% of 
subjects 
switched to 
2nd line over 
costing 
period. 
SA4 $2,761 2005 Average cost per ART 
patient based on patient 
and site records. 
ARVs, lab, 
personnel, 
infrastructure, 
management 
OI treatment  and 
inpatient care 
unclear. 
2% of 
subjects 
switched to 
2nd line over 
costing 
period. 
SA5 $1,023 2003 Resource use and cost 
data from local cohort; 
modeled annual cost.b 
ARVs, lab, OI 
treatment, inpatient 
care, personnel, 
infrastructure.  
Includes TB 
treatment. 
 0.48% of 
subjects 
switched to 
2nd line after 
6 months. 
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Study 
reference 
number 
Average 
cost/ 
patient/ 
year (USD) 
USD 
year 
Costing methods Costs included Major costs 
excluded 
Inclusion of 
2nd-line ARV 
regimen 
SA6 $2,173 2002 Average cost of claims 
reimbursed per patient-
year in 2002 for patients 
registered on program in 
1999 with starting CD4 
count 100-200.   
All claims to the 
managed care 
scheme (inpatient 
care, outpatient 
care, ARVs, lab). 
Unclear.  Not all 
subjects on ART 
for full year.   
Unspecified. 
SA7 $1,031 2004 Local regimen and input 
prices, modeled costs. 
ARVs, lab, 
personnel, 
infrastructure 
OI treatment, 
inpatient care. 
1st line only. 
SA8 $1,541 N.A. Resource use and cost 
data from local cohort; 
modeled annual cost.c 
ARVs, lab, OI 
treatment, inpatient 
care, personnel, 
infrastructure. 
 Unspecified. 
SA9 $1,322 2005 Average cost of treatment 
per patient based on 
patient and clinic records.d 
ARVs, lab, OI 
treatment, 
personnel, 
infrastructure. 
Inpatient care. Unclear, 
probably 1st 
line only. 
SA10 $784 2005 Average cost per patient in 
the 12 months following 
medical eligibility for ART. 
ARVs, lab, OI 
treatment, 
personnel, 
infrastructure.  Cost 
of subjects who 
discontinued 
treatment included. 
Inpatient care.  
Most subjects on 
ART for < 12 
months. 
14% of 
subjects 
received at 
least one 2nd 
line drug 
during costing 
period. 
U1 $412 2003 Local regimen and input 
prices, modeled with 
AIDSTreatCost. 
ARVs, lab, 
personnel. 
Inpatient care, OI 
treatment, 
infrastructure 
10% of 
patients 
assumed to 
be on 2nd 
line regimen. 
Z1 $488  2003 Local regimen and input 
prices, modeled with 
AIDSTreatCost. 
ARVs, lab.  ARV and 
lab costs increased 
by 15% to account 
for wastage. 
OI treatment, 
inpatient care, 
personnel, 
infrastructure. 
1st line only. 
N.A. = not available 
a Cost shown is base case cost per life year gained, discounted 3%. 
bCost shown is average cost/life year gained, undiscounted. 
cCost shown is average cost/life year gained, discounted 3% 
dCost shown is cost is for month 1 + month 2 + average cost/month x 10 
 
Figure 1.  Average Cost per Patient per Year, in Ascending Cost Order 
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The specific items included in the cost estimates also vary.  All of the estimates included the 
cost of ARVs and laboratory tests.  The most complete estimates also included treatment of 
opportunistic infections, inpatient care, personnel (staffing) for outpatient care, and 
infrastructure.  Some also accounted for the cost of program management.  In most cases, 
treatment of opportunistic infections excluded tuberculosis, which is often treated at a 
separate facility.  In some studies, small cost items were lumped together under an “other” 
category.  To the extent possible, we indicate in Table 2 which items are included in or 
excluded from the total provided. 
 
Finally, for studies that provided this information, the breakdown of the annual average cost 
into its main components is shown in Table 3.   
 
Table 3.  Distribution of Total Cost per Patient per Year in the Reviewed Studies 
 
Study reference number ARVs lab personnel infrastructure other 
B1 77% (other) (other) (other) 23% 
C1 25% (other) (other) (other) 75% 
E1 67% 29% 2% excluded 3% 
N1 50% 23% 22% excluded 6% 
R1 75% (other) (other) (other) 25% 
SA1 48% (other) (other) (other) 52% 
SA2 30%a 28% 18% 1% 23%d 
SA3 26%a 15% 29% 5% 26%d 
SA4 29%a 28% 25% 1% 17%d 
SA5 33%b 9% 17% 41%c 0% 
SA7 44% 24% 23% 2% 7% 
SA9 34% 18% 33% 9% 5% 
SA10 53%b 19% 18% 9% 0% 
U1 78% 18% 4% excluded 0% 
ZI 57% 36% excluded excluded 7% 
aMay include non-ARV drugs 
bIncludes non-ARV drugs 
cIncludes non-clinical personnel costs 
dPrimarily program management 
 
Discussion 
 
This review of the cost of providing antiretroviral therapy for HIV/AIDS in sub-Saharan 
Africa has three main limitations, beyond the small number of studies available for review.  
First, the cost estimates included here were drawn from a range of verified and unverified 
sources of variable quality.  In several cases, only conference abstracts or slides or project 
reports were available.  Abstracts rarely provide sufficient detail about methods or sources of 
data to allow for quality appraisal.  While there is no reason to believe that the information 
provided is not an accurate reflection of costs at the time of the studies, many of the estimates 
were never scrutinized by external reviewers.  They should thus be interpreted with caution.   
 
The second limitation involves the age of the cost estimates.  Antiretroviral drugs comprise 
the largest share of the total cost per patient in most studies, and the price of ARVs has fallen 
dramatically in the past three years.  Prices for some laboratory tests, such as CD4 counts, 
have also come down.  The older studies included in the review may therefore overestimate 
the current cost of providing ART.   
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Finally, the inconsistency in costing methods make comparison across studies hazardous.  
Each of the studies reviewed here used a different methodology for selecting costs to include, 
identifying resource utilization patterns, and assigning unit costs.  Some presented only a 
discounted average cost per life year gained, others a marginal cost per patient-year added.  
Many excluded potentially major cost items, such as infrastructure, on the grounds that 
clinics and hospitals already exist and therefore do not contribute to the incremental cost of 
providing ART.   
 
Despite these limitations, the studies reviewed in Table 2 do offer a ballpark indication of the 
cost of providing antiretroviral therapy in service delivery settings.  This cost has so far 
averaged roughly $850/patient/year in countries outside South Africa and about 
$1,700/patient/year in South Africa.  In both cases, median costs are slightly lower, at 
roughly $700/patient/year in non-South Africa countries and $1,500/patient/year in South 
Africa.  The apparently higher costs in South Africa probably reflect both higher input prices 
and more complete cost estimates.  If only the four South African studies that used recent 
cost data from public or nongovernmental sites (SA5, SA8, SA9, and SA10) are included, the 
average cost/patient/year is just under $1,200.  This may represent a more accurate estimate 
of recent costs in South Africa.  For non-South African countries, the mean cost is heavily 
influenced by the four estimates made with the AIDSTreatCost model (E1, N1, U1, and Z1), 
each of which excluded several major cost items. 
 
Of the 17 cost estimates found, 10 come from a single country, South Africa.  While it is not 
surprising that more research is being conducted in South Africa than in other countries, the 
generalizability of South African data to other countries in sub-Saharan Africa is uncertain.  
Labor costs are substantially higher in South Africa than elsewhere on the continent; on the 
other hand, transport and procurement systems are better developed and volumes of patients 
larger, which may bring costs down.   
 
Across all the studies, ARV medications comprise a large proportion of the total cost per 
patient, but this proportion varies widely.  In South Africa, ARVs account for, on average, 
just over one third of the total cost/patient, while in other countries, one half to three quarters 
of the total is attributable to ARVs.  This likely reflects the higher cost of non-ARV inputs in 
South Africa, particularly labor and inpatient care.  Some but not all of the studies reflect the 
low negotiated prices for ARVs that have been available in developing countries since 2004.   
 
Perhaps the most striking finding of this review is the sheer dearth of high quality data 
available on the cost of providing antiretroviral therapy for HIV/AIDS in service delivery 
settings in Africa.  While this may be an artifact of timing—it may simply be too soon for 
cost estimates from ART rollouts to have been published—the publication of clinical data 
from at least half a dozen national programs in multiple countries suggests otherwise.  The 
absence of cost estimates is almost certainly also a reflection of the lack of attention to 
economic aspects of national programs among researchers and research funders.  Costing is 
the simplest form of economic analysis, and among health economists, costing of service 
delivery interventions is often of less interest than modeling the cost effectiveness of 
potential interventions.  Given the importance of accurate cost information to the 
sustainability of the treatment effort, however, generating this information, from a wide range 
of countries and settings, should be given high priority in the coming months. 
 
The studies reviewed here provide little guidance to policy makers and program planners 
about the variation in costs associated with the location, scale, or sector (government, 
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nongovernmental, private) of facilities and programs,[3] the characteristics of the patient 
population, or the age of the treatment programs and concomitant average patient duration on 
ART.  Now that large scale rollouts are underway, each of these issues can and should be 
investigated through operational research.   
 
A second general finding of this review is the need for more consistent costing methods 
across countries and sites.  Accepted methods for cost analysis and presentation of cost 
information do exist.[28]   While no specific methodology can be imposed on researchers, 
wider use of standard costing methods and greater clarity in stating assumptions and 
approaches would greatly improve the quality of available data.   
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